Sepsis Therapeutics Market Report 2026

Sepsis Therapeutics Market Overview

• Sepsis Therapeutics market size has reached to $4.39 billion in 2025 • Expected to grow to $6.92 billion in 2030 at a compound annual growth rate (CAGR) of 9.5% • Growth Driver: Increasing Prevalence Of Infectious Diseases Fuelling The Growth Of The Market Due To Rising Global Health Risks And Drug-Resistant Pathogens • Market Trend: Innovative Diagnostic Technologies Enhancing Sepsis Detection And Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sepsis Therapeutics Market?

Sepsis therapeutics encompass the medical treatments and drugs designed to treat sepsis, a critical condition resulting from the body’s severe reaction to infection. The goal of these therapies is to control the infection, maintain vital functions, manage inflammation, and prevent organ failure, ultimately improving survival rates and patient recovery. The main drug class of sepsis therapeutics are cephalosporins, aminoglycosides, glycopeptides, and others. Cephalosporins, being broad-spectrum antibiotics, are commonly used to treat sepsis and other severe bacterial infections. These medications can be administered through various routes, including oral, injectable, and topical forms. They are distributed via multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies. These are mainly utilized in various applications such as hospitals, clinics, and other healthcare settings.

What Is The Sepsis Therapeutics Market Growth Forecast?

The sepsis therapeutics market size is expected to see strong growth in the next few years. It will grow to $6.92 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to development of novel antibiotic classes and biologics, increasing investment in sepsis research, expansion of hospital critical care units, adoption of advanced patient monitoring technologies, integration of telemedicine and digital health solutions. Major trends in the forecast period include rising adoption of injectable sepsis therapeutics, expansion of hospital and critical care facilities, development of broad-spectrum antibiotics, increasing focus on patient monitoring and early diagnosis, growth in telemedicine and remote healthcare solutions.

Global Sepsis Therapeutics Market Segmentation

1) By Drug Class: Cephalosporin, Aminoglycosides, Glycopeptide, Other Drug Classes 2) By Route Of Administration: Oral, Injectable 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By Application: Hospitals, Clinics, Other Applications Subsegments: 1) By Cephalosporin: First-Generation Cephalosporins, Second-Generation Cephalosporins, Third-Generation Cephalosporins, Fourth-Generation Cephalosporins, Fifth-Generation Cephalosporins 2) By Aminoglycosides: Gentamicin, Amikacin, Tobramycin, Streptomycin, Other Aminoglycosides 3) By Glycopeptide: Vancomycin, Teicoplanin, Dalbavancin, Oritavancin, Other Glycopeptides 4) By Other Drug Classes: Carbapenems, Beta-Lactamase Inhibitors, Fluoroquinolones, Macrolides, Polymyxins

What Is The Driver Of The Sepsis Therapeutics Market?

The increasing prevalence of infectious disease is expected to propel the growth of the sepsis therapeutics market going forward. Infectious diseases refer to illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites. The increasing prevalence of infectious diseases is mainly due to climate change, as rising temperatures and changing ecosystems expand the habitats of disease-carrying vectors such as mosquitoes, resulting to the spread of illnesses such as malaria and dengue fever. Sepsis therapeutics treat infectious diseases by targeting the underlying infection, reducing inflammation, and supporting organ function to prevent life-threatening complications. For instance, in January 2023, according to the National Library of Medicine, a US-based medical library for research and information, infectious diseases account for over 52 million deaths annually, placing half of the global population at risk. Each year, approximately 14 million children under the age of five die, with 70% of these deaths attributed to diseases that could be prevented through vaccination. Therefore, the increasing prevalence of infectious disease is driving growth of the sepsis therapeutics industry.

Key Players In The Global Sepsis Therapeutics Market

Major companies operating in the sepsis therapeutics market are Pfizer Inc, AstraZeneca plc, GSK plc, Eli Lilly and Company, Viatris Inc, Astellas Pharma Inc, La Jolla Pharmaceutical Company, Aridis Pharmaceuticals Inc, Partner Therapeutics Inc, InflaRx GmbH, Adrenomed AG, Sepsia Therapeutics, Endpoint Health, Prenosis Inc, Spectral Medical Inc, Modus Therapeutics, Cytovale Inc, T2 Biosystems Inc, AbbVie Inc, Merck and Co Inc

Global Sepsis Therapeutics Market Trends and Insights

Major companies operating in the sepsis diagnostics market are focusing on advancements in diagnostic tools such as development of rapid molecular tests to enable early and accurate detection of sepsis, improve patient outcomes, and reduce mortality rates associated with delayed diagnosis. Rapid molecular tests are quick diagnostic methods that identify pathogens by detecting their genetic material using advanced techniques such as PCR or isothermal amplification. For instance, in November 2023, Inflammatix Inc., a US-based biotechnology research company, announced the completion of technical development for its TriVerity Acute Infection and Sepsis Test System, comprising the Myrna Instrument and the TriVerity Cartridge. TriVerity is intended for use in emergency department settings to assess the likelihood of bacterial or viral infections and the risk of acute decompensation in patients with suspected acute infection and sepsis.

What Are Latest Mergers And Acquisitions In The Sepsis Therapeutics Market?

In January 2025, Partner Therapeutics, Inc. (PTx), a US-based biotechnology company that offers sepsis therapeutics, collaborated with the Biomedical Advanced Research and Development Authority (BARDA) to fund a Phase 2 study assessing the safety and optimal dosing of LEUKINE (sargramostim, rhu GM-CSF) in sepsis patients. This collaboration seeks to enhance sepsis treatment by developing tools to measure immune status, facilitating targeted immunomodulatory therapy. Biomedical Advanced Research and Development Authority (BARDA) is a US-based government department for biomedical advanced research.

Regional Outlook

North America was the largest region in the sepsis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Sepsis Therapeutics Market?

The sepsis therapeutics market consists of revenues earned by entities providing services such as pharmaceutical interventions, supportive therapies, and diagnostic solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The sepsis therapeutics market also includes sales of antibiotics, intravenous fluids, vasopressors, and advanced therapies aimed at controlling infection, stabilizing patients, and preventing organ failure. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.